[go: up one dir, main page]

PL3196200T3 - Pochodne 2-aminotiazolu lub jego sól jako ligandy muskarynowe m3 do leczenia chorób pęcherza moczowego - Google Patents

Pochodne 2-aminotiazolu lub jego sól jako ligandy muskarynowe m3 do leczenia chorób pęcherza moczowego

Info

Publication number
PL3196200T3
PL3196200T3 PL15836701T PL15836701T PL3196200T3 PL 3196200 T3 PL3196200 T3 PL 3196200T3 PL 15836701 T PL15836701 T PL 15836701T PL 15836701 T PL15836701 T PL 15836701T PL 3196200 T3 PL3196200 T3 PL 3196200T3
Authority
PL
Poland
Prior art keywords
muscarinic
ligands
salt
treatment
bladder diseases
Prior art date
Application number
PL15836701T
Other languages
English (en)
Inventor
Taisuke Takahashi
Hiroaki Tanaka
Michinori AKAIWA
Kenji Negoro
Hisashi Mihara
Hideyoshi FUJI
Hajime Takamatsu
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of PL3196200T3 publication Critical patent/PL3196200T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL15836701T 2014-08-26 2015-08-25 Pochodne 2-aminotiazolu lub jego sól jako ligandy muskarynowe m3 do leczenia chorób pęcherza moczowego PL3196200T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014171092 2014-08-26
PCT/JP2015/073914 WO2016031833A1 (ja) 2014-08-26 2015-08-25 2-アミノチアゾール誘導体またはその塩
EP15836701.1A EP3196200B1 (en) 2014-08-26 2015-08-25 2-aminothiazole derivatives or salt thereof as muscarinic m3 ligands for the treatment of bladder diseases

Publications (1)

Publication Number Publication Date
PL3196200T3 true PL3196200T3 (pl) 2019-09-30

Family

ID=55399719

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15836701T PL3196200T3 (pl) 2014-08-26 2015-08-25 Pochodne 2-aminotiazolu lub jego sól jako ligandy muskarynowe m3 do leczenia chorób pęcherza moczowego

Country Status (14)

Country Link
US (1) US9844549B2 (pl)
EP (1) EP3196200B1 (pl)
JP (1) JP6569678B2 (pl)
KR (1) KR20170042608A (pl)
CN (1) CN106573928B (pl)
BR (1) BR112017003901A2 (pl)
CA (1) CA2959290A1 (pl)
ES (1) ES2736098T3 (pl)
MX (1) MX2017002500A (pl)
PL (1) PL3196200T3 (pl)
PT (1) PT3196200T (pl)
RU (1) RU2702106C2 (pl)
TR (1) TR201908031T4 (pl)
WO (1) WO2016031833A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7235047B2 (ja) 2018-05-08 2023-03-08 日本新薬株式会社 アザベンゾイミダゾール化合物及び医薬

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308833A3 (en) 1999-04-15 2011-09-28 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CN1319967C (zh) 2002-01-18 2007-06-06 安斯泰来制药有限公司 2-酰基氨基噻唑衍生物或其盐
EP1499598A1 (en) 2002-04-18 2005-01-26 Ucb, S.A. Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions
CN1835948B (zh) 2003-07-17 2010-05-26 安斯泰来制药有限公司 2-酰基氨基噻唑衍生物或其盐
GB0516313D0 (en) * 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP2121688A1 (en) * 2007-02-15 2009-11-25 Argenta Discovery Ltd Heterocyclic derivatives as m3 muscarinic receptors
RU2461551C2 (ru) * 2007-10-24 2012-09-20 Астеллас Фарма Инк. Азолкарбоксамидное соединение или его фармацевтически приемлемая соль
PT2598483T (pt) 2010-07-29 2020-10-12 Rigel Pharmaceuticals Inc Compostos heterocíclicos de ativação de ampk e métodos de utilização dos mesmos
KR20180008918A (ko) * 2010-08-03 2018-01-24 앨씨알엑스, 인크. 과민성 방광 치료를 위한 베타-3 아드레날린 수용체 작용제 및 무스카린 수용체 길항제의 약학적 배합제
JP6112316B2 (ja) 2011-12-22 2017-04-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung テトラアザ−シクロペンタ[a]インデニル及びポジティブアロステリックモジュレーターとしてのそれらの使用
JP6211509B2 (ja) 2012-03-02 2017-10-11 武田薬品工業株式会社 複素環化合物およびその用途
US9777005B2 (en) 2012-11-19 2017-10-03 Takeda Pharmaceutical Company Limited Bicyclic heterocyclic compound containing a substituted pyrrole ring
TWI647227B (zh) * 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 2-醯胺噻唑衍生物或其鹽
PT3153511T (pt) 2014-06-06 2019-06-28 Astellas Pharma Inc Derivado de 2-acilaminotiazole para utilização na prevenção ou tratamento de doenças da bexiga/trato urinário

Also Published As

Publication number Publication date
WO2016031833A1 (ja) 2016-03-03
RU2017105450A (ru) 2018-09-27
RU2017105450A3 (pl) 2019-03-19
RU2702106C2 (ru) 2019-10-04
CA2959290A1 (en) 2016-03-03
KR20170042608A (ko) 2017-04-19
EP3196200A4 (en) 2018-02-28
MX2017002500A (es) 2017-05-23
EP3196200A1 (en) 2017-07-26
JPWO2016031833A1 (ja) 2017-06-22
PT3196200T (pt) 2019-06-17
BR112017003901A2 (pt) 2017-12-12
EP3196200B1 (en) 2019-05-08
CN106573928A (zh) 2017-04-19
ES2736098T3 (es) 2019-12-26
US9844549B2 (en) 2017-12-19
CN106573928B (zh) 2020-04-14
US20170290824A1 (en) 2017-10-12
JP6569678B2 (ja) 2019-09-04
TR201908031T4 (tr) 2019-06-21

Similar Documents

Publication Publication Date Title
IL272820A (en) History of sulfamolepyrolamide and their use as hepatitis B drugs
SMT201900172T1 (it) Ammino triazoli sostituiti utili come inibitori della chitinasi umana
IL259281B (en) History of bipyrazolyl used in the treatment of autoimmune diseases
IL249502A0 (en) Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases
PL3210973T3 (pl) Związki heteroarylowe do leczenia chorób oczu
ZA201807509B (en) Di-substituted pyrazole compounds for the treatment of diseases
IL246721B (en) History of 5-benzylisoquinoline for the treatment of cardiovascular diseases
IL259297A (en) Heterocyclic compounds for the treatment of disease
EP3137907A4 (en) Methods and compositions for the diagnosis and treatment of kawasaki disease
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
EP3145525A4 (en) Use of microperoxidases for the treatment of carboxyhemoglobinemia
PT3196200T (pt) Derivados de 2-aminotiazol ou sal do mesmo, como ligantes muscarínico m3 para o tratamento das doenças da bexiga
HK40070316B (zh) 用於治疗疾病的杂环化合物
ZA201704589B (en) Compounds for the treatment of cancer
PL3194360T3 (pl) Pochodne 4-okso-N-(4-hydroksyfenylo)retinamidu jako środki terapeutyczne do leczenia raka
HK1233709A1 (en) Methods and compositions for the diagnosis and treatment of kawasaki disease